Antivenom: The most cost-effective treatment in the world?
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The substantial morbidity and mortality resulting globally from snakebite may seem surprising considering that antivenoms (whole IgG molecules, Fab or F(ab′)2 fragments from venom-immunized animals) are often highly effective at recognizing and neutralizing the major toxic components of a venom (19, 20).”
From Assessing Target Specificity of the Small Molecule Inhibitor MARIMASTAT to Snake Venom Toxins: A Novel Application of Thermal Proteome Profiling (2024) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence
Creese, A., Floyd, K., Alban, A., & Guinness, L. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08595-1 · Cited by 394 · cited 1×
“Numerous research articles have estimated the cost per DALY saved with first or second line ART in African countries to be between US$395 and US$2010 (Creese et al., 2002; Marseille et al., 2002; Marsaki et al., 2003; Canning, 2006; Hogan et al., 2005; Brent, 2009).”
Background
Research works printed but not linked: 9
- Brent, 2009, An implicit price of a DALY for use in a cost-benefit analysis of ARVs, Applied Economics, 1466
- Canning, 2006, The economics of HIV/AIDS in low countries: the case for prevention, Journal of Economic Perspectives, 20, 121, 10.1257/jep.20.3.121 · DOI
- Fox-Rushby, 2001, Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis, Health Policy and Planning, 16, 326, 10.1093/heapol/16.3.326 · DOI · Paper page
- Habib, 2008, Envenoming after carpet viper (Echis ocellatus) bite during pregnancy: timely use of effective antivenom improves maternal and foetal outcomes, Trop Med Int Health, 13, 1172, 10.1111/j.1365-3156.2008.02122.x · doi:10.1111/j.1365-3156.2008.02122.x
- Hogan, 2005, Cost-effectiveness analysis of strategies to combat HIV/AIDS in developing countries, British Medical Journal, 331, 1431, 10.1136/bmj.38643.368692.68 · DOI · Paper page
- Marseille, 2002, HIV prevention before HAART in sub-Saharan Africa, Lancet, 359, 1851, 10.1016/S0140-6736(02)08705-6 · DOI · Paper page
- Theakston, 2000, Crisis in snake antivenom supply for Africa, Lancet, 356, 2104, 10.1016/S0140-6736(05)74319-1 · DOI · Paper page
- Warrell, 1977, Poisoning by bites of the saw-scaled or carpet viper (Echis carinatus) in Nigeria, Quaterly Journal of Medicine, 46, 33
- Warrell, 2008, Unscrupulous marketing of snake bite antivenoms in Africa and Papua New Guinea: choosing the right product-‘What's in a name?’, Transactions of the Royal Society of Tropical Medicine and Hygiene, 102, 397, 10.1016/j.trstmh.2007.12.005 · doi:10.1016/j.trstmh.2007.12.005
Cited by
Hall, S. R., Rasmussen, S. A., Crittenden, E., Dawson, C. A., Bartlett, K. E., Westhorpe, A. P., Albulescu, L.-O., Kool, J., Gutiérrez, J. M., & Casewell, N. R. (2023) · Nature Communications · doi:10.1038/s41467-023-43510-w · Cited by 63
Smith, C. F., Modahl, C. M., Ceja Galindo, D., Larson, K. Y., Maroney, S. P., Bahrabadi, L., Brandehoff, N. P., Perry, B. W., McCabe, M. C., Petras, D., et al. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100779 · Cited by 11
Metadata
- Authors
- Brown, N., & Landon, J.
- Venue
- Toxicon
- Publisher
- Elsevier BV
- Published
- 2010-06
- Volume
- 55
- Issue
- 7
- Pages
- 1405-1407
- ISSN
- 0041-0101
- Cited by
- 60
- References
- 1
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antivenom: The most cost-effective treatment in the world? https://app.cochat.ai/papers/10.1016/j.toxicon.2010.02.012
- The paper
- Brown, N., & Landon, J. (2010). Antivenom: The most cost-effective treatment in the world? Toxicon. https://doi.org/10.1016/j.toxicon.2010.02.012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.